Description
Pomalidomide Capsules is used for two main conditions in adults:
- Treating Multiple Myeloma (MM):
- Given with dexamethasone after at least two prior treatments, including lenalidomide and a proteasome inhibitor, for those whose disease got worse despite previous therapies.
- Addressing AIDS-Related Kaposi Sarcoma (KS):
- Used when standard HIV treatments fail for AIDS-related KS. Also considered for KS in HIV-negative patients, but more evidence is needed from additional studies.
Dosage and Side Effects of Pomalidomide Capsule
- For Multiple Myeloma (MM):
- Take a Pomalidomide 4 mg capsule once daily for 21 days in a 28-day cycle until the disease worsens.
- Follow specific guidelines for taking dexamethasone along with Pomalidomide.
- For Kaposi Sarcoma (KS):
- Take a 5 mg capsule once daily for 21 days in a 28-day cycle until the disease worsens or if there are side effects.
- Adjustments:
- Doctors might change the dose for patients with kidney or liver issues.
- For Multiple Myeloma (MM): The most common side effects include tiredness, weakness, low white blood cells, low red blood cells, constipation, nausea, diarrhea, breathing problems, infections, back pain, and fever.
- For Kaposi Sarcoma (KS): Common side effects include changes in blood counts, kidney function, skin rash, constipation, tiredness, low red blood cells, low platelets, low phosphate, low albumin, high liver enzymes, nausea, and diarrhea.
Warning and Precautions of Pomalidomide Capsule
- When combining pembrolizumab with dexamethasone and a thalidomide-like drug for multiple myeloma, higher mortality rates were noted.
- Hematologic toxicity, particularly neutropenia, requires close patient monitoring.
- Hepatotoxicity resulting in liver failure, albeit rare, necessitates monthly liver function tests.
- Immediate discontinuation of Pomalidomide is crucial if severe skin reactions occur.
- Patients with a high tumor burden should be closely monitored for Tumor Lysis Syndrome (TLS) and preventative measures taken.
- Regular monitoring for potential hypersensitivity reactions, with prompt discontinuation if angioedema or anaphylaxis arises.
